Details of the Drug

General Information of Drug (ID: DMMEAOL)

Drug Name
Coversin
Indication
Disease Entry ICD 11 Status REF
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [1]
Drug Type
Recombinant?protein
Cross-matching ID
TTD ID
DYG0W5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Paroxysmal nocturnal haemoglobinuria
ICD Disease Classification 3A21.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03427060) Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms (CONSENTII). U.S. National Institutes of Health.
2 Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.